{"product_id":"blco-bcg-matrix","title":"(BLCO) Bausch + Lomb Corporation BCG Matrix Research","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-List-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eUnlock Strategic Clarity\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eThis Bausch + Lomb Corporation BCG Matrix is a company-specific framework used to assess the portfolio across Stars, Cash Cows, Question Marks, and Dogs, helping with strategy, investment, and business planning. The content on this page is a real preview of the actual analysis, not just marketing text, so you can see the format and depth before buying. Purchase the full version to get the complete ready-to-use report.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eStars\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eULTRA premium contact lenses\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eULTRA is Bausch + Lomb Corporation’s premium monthly contact lens line, and it fits the Star bucket because higher-value daily and specialty fits keep gaining share. The brand strengthens Vision Care’s mix in a segment that Bausch + Lomb continued to invest in through new launches and product upgrades in 2025. That supports stronger pricing power and helps ULTRA stay tied to an expanding category.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eXiidra dry-eye prescription brand\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eXiidra stayed a key branded dry-eye therapy, and Bausch + Lomb reported about $3.8 billion in 2024 revenue, showing the scale behind its eye-care franchise. With dry-eye affecting roughly 16 million U.S. adults, the brand still benefits from strong prescriber awareness and repeat use. If share and growth hold, Xiidra fits a Star in BCG terms.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eenVista IOL platform\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eenVista IOL platform is tied to cataract surgery, a large procedure market with roughly 4 million U.S. cases a year and steady demand from aging demographics. Premium intraocular lens adoption supports pricing and keeps the franchise relevant as surgeons seek better visual outcomes. With new lens options and surgical pull-through, enVista still fits a Star profile because demand can keep rising while the category stays large.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eLUMIFY OTC redness reliever\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eLUMIFY OTC redness reliever acts like a Star in Bausch + Lomb Corporation’s portfolio because it is one of the best-known consumer eye-care brands and sits in a repeat-buy OTC category. Its branded position supports pricing power, and strong shelf space plus promotion can keep demand high. The franchise fits a Star profile as long as growth stays above the mature eye-care market.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eHigh brand awareness\u003c\/li\u003e\n\u003cli\u003eRepeat purchase category\u003c\/li\u003e\n\u003cli\u003eStrong retail visibility\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eBLINK dry-eye consumer line\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eBLINK sits in a growing dry-eye and comfort category, and Bausch + Lomb keeps it broad with tears plus related self-care products. That gives it Star potential: demand is still widening, and daily-use eye care keeps pulling in new users across 2025-2026.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eDry-eye need is still expanding.\u003c\/li\u003e\n\u003cli\u003eBLINK covers tears and self-care.\u003c\/li\u003e\n\u003cli\u003eConsumer eye-care demand is widening.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eULTRA, Xiidra and enVista Power Bausch + Lomb’s Growth\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eULTRA, Xiidra, enVista, LUMIFY, and BLINK fit Stars because they sit in large, still-growing eye-care niches with repeat use, premium pricing, and strong brand pull. Xiidra benefits from about 16 million U.S. adults with dry eye, while enVista rides roughly 4 million U.S. cataract cases a year. Bausch + Lomb’s 2025 product push helps keep these brands in growth mode.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eBrand\u003c\/th\u003e\n\u003cth\u003eStar driver\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eXiidra\u003c\/td\u003e\n\u003ctd\u003eDry-eye demand\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eenVista\u003c\/td\u003e\n\u003ctd\u003eCataract volume\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"product-includes\"\u003e\n\u003cdiv class=\"product-includes__container\"\u003e\n\u003ch2 id=\"product-includes-title\" class=\"product-includes__title\"\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-includes__grid\"\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Detailed Word Document icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eBausch + Lomb’s BCG Matrix maps its portfolio to spot Stars, Cash Cows, Question Marks, and Dogs for invest\/hold\/divest actions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Customizable Excel Spreadsheet icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eEditable Excel File\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eBausch + Lomb BCG Matrix: quick quadrant view to pinpoint pain points and guide portfolio decisions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Reference-Icon.svg\" alt=\"References icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eReference Sources\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eProvides a credible source trail for Bausch + Lomb Corporation, making key claims easier to verify and decisions easier to trust.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eCash Cows\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePreserVision AREDS 2\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003ePreserVision AREDS 2 is Bausch + Lomb Corporation’s mature eye-vitamin cash cow, anchored to the large age-related macular degeneration market, where about 20 million U.S. adults live with some form of AMD. The AREDS2 formula is backed by National Eye Institute research showing a 25% lower risk of advanced AMD progression in high-risk patients. Its wide brand recognition supports repeat sales with limited reinvestment.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBiotrue Multi-Purpose Solution\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eBiotrue Multi-Purpose Solution fits a Cash Cow because it serves an everyday contact-lens care need in a mature category with wide optical and retail reach. Bausch + Lomb’s 2024 net sales were about $4.8 billion, and a steady brand like Biotrue can keep generating cash with limited growth spend. Its value comes from repeat use, not heavy reinvestment.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eReNu Advanced Formula\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eReNu Advanced Formula is a legacy contact lens care brand with long shelf life in a low-growth, repeat-purchase category. That makes it a Cash Cow in Bausch + Lomb Corporation’s BCG Matrix: demand is driven by an installed user base, not fast expansion. The company’s recent filings still show contact lens care as a steady cash-generating line versus newer growth bets.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eLUMIFY consumer eye care\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eLUMIFY consumer eye care fits the Cash Cow box because it has strong brand recognition, repeat retail demand, and a mature redness-relief market. Once shelf space and pharmacy distribution are secured, the product can keep selling with tighter, more efficient marketing spend. Bausch + Lomb does not separately disclose LUMIFY sales, but the brand remains a steady consumer franchise.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eHigh awareness drives repeat buys\u003c\/li\u003e\n\u003cli\u003eMature category limits growth but supports cash\u003c\/li\u003e\n\u003cli\u003eLocked-in distribution lowers spend needs\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eVyzulta glaucoma therapy\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eVyzulta is a mature prescription glaucoma therapy in a chronic-use market, so it benefits from repeat refills and stable demand. Bausch + Lomb reported 2024 net sales of about $4.6 billion, and a branded eye-drop with intact access and steady prescribing fits a Cash Cow profile when growth is no longer the main driver.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eChronic therapy supports recurring revenue\u003c\/li\u003e\n\u003cli\u003eOpen-angle glaucoma needs long-term treatment\u003c\/li\u003e\n\u003cli\u003eStable access keeps cash flow durable\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBausch + Lomb’s Cash Cows Keep the Engine Running\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eCash Cows at Bausch + Lomb Corporation are mature, repeat-use brands that keep generating cash with limited spend. PreserVision AREDS 2, Biotrue, ReNu, LUMIFY, and Vyzulta all fit that pattern because they sell into large, stable eye-care markets. Bausch + Lomb reported about $4.8 billion 2024 net sales, so these lines help fund growth bets.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eBrand\u003c\/th\u003e\n\u003cth\u003eCash role\u003c\/th\u003e\n\u003cth\u003eWhy\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003ePreserVision\u003c\/td\u003e\n\u003ctd\u003eCash Cow\u003c\/td\u003e\n\u003ctd\u003eAMD repeat buys\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eBiotrue\u003c\/td\u003e\n\u003ctd\u003eCash Cow\u003c\/td\u003e\n\u003ctd\u003eDaily lens care\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003ePreview the Actual Deliverable\u003c\/span\u003e\u003cbr\u003eBausch + Lomb Corporation Reference Sources\u003c\/h2\u003e\n\u003cp\u003eThe Bausch + Lomb Corporation BCG Matrix preview you see here is the exact document you’ll receive after purchase. It includes the full, professionally formatted analysis with no demo content or hidden sections. Once purchased, the complete file is instantly available for your strategic review, presentation, or planning needs. What you see now is what you get.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eDogs\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePureVision 2 monthly lenses\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003ePureVision 2 monthly lenses fit Bausch + Lomb Corporation's Dog bucket in the BCG Matrix: they are a legacy, older-format product with limited growth. Monthly lenses are under pressure from daily-disposable lenses, which now dominate premium contact lens demand and make share harder to defend. In a market where one-day lenses keep taking mix, PureVision 2 is low-growth and likely low-share.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSofLens legacy lens family\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eSofLens is an older soft-lens family in a crowded market now led by premium and daily disposable formats. That puts it in the Dogs box: low growth, weak share, and steady pressure as wearers shift to newer modalities. For Bausch + Lomb Corporation, the brand can still serve legacy users, but it needs ongoing support even as demand drifts down.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eOlder generic ophthalmic products\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eOlder generic ophthalmic products fit the Dog quadrant because they compete mainly on price, with low differentiation and thin margins. In Bausch + Lomb's mix, these products usually face weak growth and limited share gains as commoditized molecules lose pricing power. That makes capital returns low unless volume can scale fast enough to offset squeeze.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eLegacy surgical hardware lines\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eLegacy surgical hardware sits in the Dogs box because hospitals keep shifting to more automated systems, so upgrade demand stays weak. In Bausch + Lomb Corporation’s 2025 surgical mix, newer platforms like H2 systems and digital-guided tools matter more than older hardware lines, which face replacement cycles and lower pricing power. That makes these products low-growth and hard to defend.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eWeak upgrade demand\u003c\/li\u003e\n\u003cli\u003eShift to automated platforms\u003c\/li\u003e\n\u003cli\u003eLower pricing power\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eWhen surgeons standardize on higher-feature systems, legacy hardware usually loses share fast.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eLow-volume regional OTC packs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eLow-volume regional OTC packs fit Dogs in Bausch + Lomb Corporation’s BCG Matrix because they usually lack national brand pull and need local selling to move. With narrow distribution and weak scale, each small pack can soak up shelf, promo, and logistics cost without lifting share.\u003c\/p\u003e\n\u003cp\u003eThat is why they tend to stay cash traps, not growth engines.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eLow brand power\u003c\/li\u003e\n\u003cli\u003eNarrow regional reach\u003c\/li\u003e\n\u003cli\u003ePoor promo ROI\u003c\/li\u003e\n\u003cli\u003eResource drag\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLegacy Bausch + Lomb Dog Lines Still Drain Cash in 2025\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eDogs in Bausch + Lomb Corporation’s BCG Matrix are legacy lines like PureVision 2, SofLens, older ophthalmics, and low-volume regional OTC packs. They face low growth, weak share, and pricing pressure as 1-day lenses and newer platforms keep taking mix. These lines usually drain cash more than they earn it.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eDog line\u003c\/th\u003e\n\u003cth\u003e2025 signal\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003ePureVision 2\u003c\/td\u003e\n\u003ctd\u003eLegacy monthly, low growth\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSofLens\u003c\/td\u003e\n\u003ctd\u003eOlder family, share pressure\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLegacy surgical hardware\u003c\/td\u003e\n\u003ctd\u003eWeak upgrade demand\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRegional OTC packs\u003c\/td\u003e\n\u003ctd\u003eLow scale, weak ROI\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eQuestion Marks\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMIEBO dry-eye therapy\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eMIEBO is still a Question Mark in Bausch + Lomb Corporation’s BCG Matrix: it is a newer dry-eye prescription launch in a large, fast-growing market, but share is still being built. Dry eye affects about 38 million people in the U.S., so the upside is real, but new brands need heavy promotion, payer access, and physician adoption. Until MIEBO scales, it stays capital-hungry and uncertain.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eINFUSE daily disposable lens\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eINFUSE daily disposable lens fits Bausch + Lomb Corporation’s Question Mark bucket because it targets the fastest-growing soft-lens format, but the brand still needs scale to win share. New lenses need real trial, fitter adoption, and heavy channel support, so launch costs stay high before repeat buying kicks in. In Bausch + Lomb Corporation’s 2025-2026 push, INFUSE is a growth bet: attractive category, still early on the adoption curve.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eenVista Envy premium IOL\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eenVista Envy sits in Question Mark because premium IOLs are still a small part of the cataract market, even as U.S. cataract surgery volumes stay above 4 million cases a year. The lens can scale fast if Bausch + Lomb wins surgeon share and converts more routine cases to premium. For now, adoption is still building, so cash needs stay high while growth is not yet proven.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eTherapeutic contact lenses\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eTherapeutic contact lenses fit Bausch + Lomb Corporation’s Question Mark bucket because they serve a narrow clinical need, not mass consumer demand. The upside is real if eye doctors adopt them more broadly, but current share stays limited versus larger vision-care lines. \u003c\/p\u003e\n\u003cp\u003eSo the play is high potential, low scale: a specialist market that can grow with stronger clinical use and reimbursement support. That makes it worth watching, but it is not yet a cash engine.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eNiche ophthalmic use\u003c\/li\u003e\n\u003cli\u003eLimited current share\u003c\/li\u003e\n\u003cli\u003eGrowth depends on adoption\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eNew ophthalmic pipeline launches\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eBausch + Lomb Corporation’s new dry eye, glaucoma, and surgical care launches are Question Marks because they can expand the base, but early wins are still unproven. In 2024, Bausch + Lomb Corporation reported about $4.8 billion in net sales, so even a small share gain from launches can matter.\u003c\/p\u003e\n\u003cp\u003eThese products usually burn cash first, with higher launch, sales, and medical education spend before revenue scales. They stay Question Marks until Bausch + Lomb Corporation shows durable share and repeat use.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eDry eye, glaucoma, surgical care launches\u003c\/li\u003e\n\u003cli\u003eHigh upfront cash use\u003c\/li\u003e\n\u003cli\u003eNeed durable market share proof\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBausch + Lomb’s Big-Bet Products: Early Growth, High Upside\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eBausch + Lomb Corporation’s Question Marks are MIEBO, INFUSE, enVista Envy, and therapeutic lenses: each sits in a big market, but 2025-2026 share is still early and cash use is high. Bausch + Lomb Corporation reported about $4.8 billion in 2024 net sales, so small gains can still matter.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eProduct\u003c\/th\u003e\n\u003cth\u003eWhy Question Mark\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eMIEBO\u003c\/td\u003e\n\u003ctd\u003eDry-eye launch\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eINFUSE\u003c\/td\u003e\n\u003ctd\u003eDaily lens growth bet\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eenVista Envy\u003c\/td\u003e\n\u003ctd\u003ePremium IOL adoption\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"DCF Analyst","offers":[{"title":"Default Title","offer_id":57234116280585,"sku":"blco-bcg-matrix","price":5.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0942\/8045\/0313\/files\/blco-bcg-matrix.webp?v=1785713174","url":"https:\/\/dcfanalyst.com\/products\/blco-bcg-matrix","provider":"DCF Analyst","version":"1.0","type":"link"}